183
Participants
Start Date
May 8, 2017
Primary Completion Date
March 6, 2018
Study Completion Date
March 6, 2018
ASP8062
ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
Placebo
Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
NY Scientific, Brooklyn
Neurobehavioral Research, Inc, Cedarhurst
Lehigh Center for Clinical Research, Allentown
PMG of Winston-Salem, LLC, Winston-Salem
Private Practice, Raleigh
Avail Clinical Research, LLC, DeLand
Clinical Neuroscience Solutions, Inc, Orlando
PAB Clinical Research, Brandon
ClinSearch, LLC, Chattanooga
Elite Clinical Research, LLC, Jackson
Neuro-Behavioral Clinical Research, Inc, Canton
University of Cincinnati, Cincinnati
Medisphere Medical Research Center, LLC, Evansville
Clinical Investigation Specialists, Inc, Kenosha
Meridian Clinical Research, Dakota Dunes
Chicago Research Center, Inc, Chicago
The Center For Pharmaceutical Research, Kansas City
Noesis Pharma, LLC, Phoenix
Advanced Biomedical Research of America, Las Vegas
Collaborative Neuroscience Network, LLC., Torrance
Excell Research, Inc, Oceanside
Summit Research Network, Portland
Infinity Medical Research, Inc, North Dartmouth
Omega Medical Research, Warwick
Astellas Pharma Global Development, Inc.
INDUSTRY